Overview

Dose-escalating Trial With UniCAR02-T Cells and CD123 Target Module (TM123) in Patients With Hematologic and Lymphatic Malignancies

Status:
Recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug UniCAR02-T-CD123 in patients with hematologic and lymphatic malignancies positive for CD123 marker. The UniCAR02-T-CD123 drug is a combination of a cellular component (UniCAR02-T) with a recombinant antibody derivative (TM123) which together forms the active drug.

Phase:

Phase 1

Details

Lead Sponsor:

Cellex Patient Treatment GmbH

Collaborator:

PHARMALOG Institut für klinische Forschung GmbH

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate